Isthmus Partners’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $16.9M | Buy |
67,124
+60
| +0.1% | +$12.9K | 1.63% | 14 |
|
|
2026
Q1 | $14.6M | Buy |
67,064
+2,324
| +4% | +$516K | 1.53% | 19 |
|
|
2025
Q4 | $14.8M | Sell |
64,740
-323
| -0.5% | -$73.6K | 1.64% | 19 |
|
|
2025
Q3 | $15.1K | Buy |
65,063
+918
| +1% | +$187K | ﹤0.01% | 133 |
|
|
2025
Q2 | $11.9M | Buy |
64,145
+62,420
| +3,619% | +$11.6M | 1.39% | 34 |
|
|
2025
Q1 | $361K | Hold |
1,725
| – | – | 0.05% | 166 |
|
|
2024
Q4 | $307K | Hold |
1,725
| – | – | 0.04% | 180 |
|
|
2024
Q3 | $341K | Hold |
1,725
| – | – | 0.04% | 165 |
|
|
2024
Q2 | $296K | Hold |
1,725
| – | – | 0.03% | 169 |
|
|
2024
Q1 | $314K | Sell |
1,725
-435
| -20% | -$75K | 0.04% | 167 |
|
|
2023
Q4 | $335K | Buy |
2,160
+100
| +5% | +$14.6K | 0.04% | 152 |
|
|
2023
Q3 | $307K | Buy |
2,060
+125
| +6% | +$18.4K | 0.04% | 148 |
|
|
2023
Q2 | $261K | Buy |
1,935
+10
| +0.5% | +$1.47K | 0.04% | 157 |
|
|
2023
Q1 | $307K | Hold |
1,925
| – | – | 0.04% | 150 |
|
|
2022
Q4 | $311K | Hold |
1,925
| – | – | 0.05% | 150 |
|
|
2022
Q3 | $258K | Hold |
1,925
| – | – | 0.04% | 150 |
|
|
2022
Q2 | $295K | Hold |
1,925
| – | – | 0.06% | 131 |
|
|
2022
Q1 | $312K | Hold |
1,925
| – | – | 0.05% | 135 |
|
|
2021
Q4 | $261K | Hold |
1,925
| – | – | 0.04% | 141 |
|
|
2021
Q3 | $208K | Buy |
1,925
+300
| +18% | +$34.3K | 0.04% | 148 |
|
|
2021
Q2 | $183K | Buy |
+1,625
| New | +$183K | 0.03% | 149 |
|
|
2020
Q3 | – | Sell |
-2,196
| Closed | -$216K | – | 141 |
|
|
2020
Q2 | $216K | Sell |
2,196
-543
| -20% | -$47.8K | 0.05% | 134 |
|
|
2020
Q1 | $209K | Buy |
+2,739
| New | +$233K | 0.06% | 127 |
|
|
2018
Q4 | – | Sell |
-1,613
| Closed | -$153K | – | 133 |
|
|
2018
Q3 | $153K | Buy |
1,613
+161
| +11% | +$15.3K | 0.04% | 133 |
|
|
2018
Q2 | $135K | Hold |
1,452
| – | – | 0.04% | 138 |
|
|
2018
Q1 | $137K | Sell |
1,452
-200
| -12% | -$22K | 0.04% | 137 |
|
|
2017
Q4 | $160K | Hold |
1,652
| – | – | 0.04% | 136 |
|
|
2017
Q3 | $147K | Buy |
1,652
+71
| +4% | +$5.41K | 0.04% | 139 |
|
|
2017
Q2 | $115K | Hold |
1,581
| – | – | 0.03% | 152 |
|
|
2017
Q1 | $103K | Sell |
1,581
-336
| -18% | -$21.1K | 0.03% | 156 |
|
|
2016
Q4 | $120K | Buy |
1,917
+297
| +18% | +$18.1K | 0.04% | 153 |
|
|
2016
Q3 | $99K | Hold |
1,620
| – | – | 0.03% | 150 |
|
|
2016
Q2 | $100K | Hold |
1,620
| – | – | 0.03% | 144 |
|
|
2016
Q1 | $93K | Hold |
1,620
| – | – | 0.03% | 146 |
|
|
2015
Q4 | $96K | Hold |
1,620
| – | – | 0.03% | 150 |
|
|
2015
Q3 | $88K | Hold |
1,620
| – | – | 0.03% | 156 |
|
|
2015
Q2 | $109K | Hold |
1,620
| – | – | 0.04% | 150 |
|
|
2015
Q1 | $95K | Hold |
1,620
| – | – | 0.03% | 149 |
|
|
2014
Q4 | $106K | Buy |
+1,620
| New | +$102K | 0.04% | 150 |
|
Other funds holding ABBV
LMFP
ATO
HCM
AAMU
FWCM
Isthmus Partners's ABBV Position: Q2 2026 in Review
Isthmus Partners increased its AbbVie (ABBV) stake by 0.09% in Q2 2026, buying an estimated $12.9K and bringing the position to 67,124 shares worth $16.9M. The position accounts for 1.63% of the portfolio, ranked #14.
Isthmus Partners first reported a position in ABBV in Q4 2014 and has held it in 39 quarters since. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Isthmus Partners held 67,124 shares of AbbVie worth $16.9M as of Q2 2026.
- Isthmus Partners bought 60 AbbVie shares in Q2 2026, an estimated $12.9K.
- AbbVie made up 1.63% of Isthmus Partners's portfolio in Q2 2026, its #14 holding.
- Isthmus Partners first reported a position in AbbVie in Q4 2014 and has held it in 39 quarters since.
- 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Isthmus Partners's 13F filing for Q2 2026, filed 20 Jul 2026.